Bisphosphonates Drug-Drug Interaction Table: A Complete Prescriber Reference

What Is the Bisphosphonates Drug Class?

Bisphosphonates are synthetic analogs of inorganic pyrophosphate. They carry two phosphonate groups flanking a central carbon atom, which gives them near-irreversible affinity for bone mineral. Once deposited in bone, they are taken up by osteoclasts and block the mevalonate pathway enzyme farnesyl pyrophosphate synthase (FPPS), triggering osteoclast apoptosis and reducing bone resorption.

The class splits into two mechanistic subgroups based on whether the R2 side chain contains nitrogen.

Non-Nitrogen Bisphosphonates

Etidronate and clodronate lack a nitrogen group. They are metabolized intracellularly to cytotoxic ATP analogs. These agents are largely obsolete in the United States for osteoporosis but remain in use for Paget disease in some international markets.

Nitrogen-Containing Bisphosphonates

Alendronate, risedronate, ibandronate, pamidronate, and zoledronic acid all carry an amino or imidazole group on the R2 side chain. This structural feature increases FPPS inhibitory potency by 10,000-fold compared with etidronate and accounts for the superior antifracture efficacy seen in clinical trials. The Fracture Intervention Trial (FIT, N=2,027) demonstrated that alendronate reduced vertebral fracture risk by 47% over three years in women with low bone density and a prior vertebral fracture (P<0.001) [1].

Approved Indications

The FDA-approved indications for this class include postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, Paget disease of bone, hypercalcemia of malignancy, and skeletal-related events in bone metastases [2]. The American Association of Clinical Endocrinologists (AACE) 2020 guidelines list bisphosphonates as preferred first-line therapy for patients with osteoporosis and a 10-year FRAX hip fracture probability of 3% or greater [3].

Pharmacokinetics: Why Interactions Happen

Understanding where interactions arise requires a clear picture of how bisphosphonates move through the body.

Absorption

Oral bioavailability is extremely low: approximately 0.6% for alendronate and 0.63% for risedronate under fasting conditions [4]. Any cation or food in the stomach during dosing precipitates chelation complexes that are not absorbed. The FDA-approved label for alendronate (Fosamax) specifies taking the tablet at least 30 minutes before the first food, beverage, or medication of the day [2].

Distribution and Bone Deposition

After absorption, 50 to 80% of the circulating dose adsorbs to bone within hours. The remainder is excreted unchanged by the kidney. Bisphosphonates do not undergo hepatic metabolism and are not substrates for CYP450 enzymes, which eliminates a large category of pharmacokinetic drug interactions seen with other drug classes [5].

Renal Elimination

Because renal clearance is the only elimination route, renal impairment prolongs skeletal half-life and increases systemic exposure after IV formulations. Zoledronic acid (Reclast) carries a contraindication for use when CrCl <35 mL/min [6]. Alendronate labeling recommends against use when CrCl <35 mL/min as well [2].

Half-Life in Bone

The terminal half-life of alendronate in bone is estimated at more than 10 years in humans. This property underlies the concept of a "drug holiday" after 5 years of oral therapy or 3 years of annual IV zoledronic acid, as recommended in the AACE/ACE clinical practice guidelines [3].

Full Bisphosphonate Drug-Drug Interaction Table

The table below is organized by interaction mechanism. Severity ratings follow standard pharmacovigilance convention: Major (avoid or contraindicated), Moderate (monitor or adjust dose/timing), Minor (minimal clinical consequence).

| Interacting Drug or Class | Bisphosphonate(s) Affected | Mechanism | Clinical Effect | Severity | Management | |---|---|---|---|---|---| | Calcium supplements | All oral BPs | Chelation of Ca²⁺ in GI tract; forms insoluble complex | Bisphosphonate AUC reduced by up to 60% | Major | Separate by at least 30 min (fasting rule); ideally 2 hr | | Antacids (Ca, Mg, Al salts) | All oral BPs | Same chelation as calcium | Near-complete absorption blockade | Major | Do not co-administer; take BP first, antacid at least 30 min later | | Iron supplements (oral) | All oral BPs | Fe²⁺ chelation in gut | Significant reduction in BP bioavailability | Major | Separate by at least 2 hr | | Magnesium supplements | All oral BPs | Mg²⁺ chelation | Reduced absorption | Moderate | Separate by at least 2 hr | | NSAIDs (ibuprofen, naproxen) | Alendronate, risedronate | Additive GI mucosal injury; both are irritants | Increased risk of esophageal and gastric ulceration | Moderate | Use with caution; prefer IV bisphosphonate in patients on chronic NSAIDs | | Aspirin (≥325 mg/day) | Alendronate | GI mucosal irritant combination | Increased upper GI adverse events | Moderate | Monitor for dyspepsia, GI bleed; consider PPI if both required | | Aminoglycosides (IV) | Zoledronic acid, pamidronate | Additive nephrotoxicity; both cause tubular injury | Acute kidney injury; additive hypocalcemia | Major | Avoid concurrent use; if unavoidable, monitor serum creatinine and calcium daily | | Loop diuretics (furosemide) | Zoledronic acid, pamidronate | Additive renal calcium wasting; diuretic-induced volume depletion worsens tubular toxicity | Hypocalcemia; nephrotoxicity | Moderate | Monitor serum Ca²⁺ and creatinine; ensure adequate hydration before IV BP | | Thalidomide | Zoledronic acid | Pharmacodynamic combination increasing renal toxicity in myeloma patients | AKI risk elevated | Moderate | Monitor renal function closely | | Glucocorticoids (chronic) | All BPs | Pharmacodynamic antagonism; glucocorticoids increase bone resorption while BPs inhibit it | Attenuated fracture-risk reduction; BP dose may need to continue throughout steroid course | Moderate | Continue BP; use risedronate or zoledronic acid per ACR guidelines for glucocorticoid-induced osteoporosis [7] | | Methotrexate | Pamidronate (case reports) | Unclear; possible competition for renal tubular secretion | Elevated methotrexate exposure; toxicity risk | Minor-Moderate | Monitor methotrexate levels if using IV pamidronate concurrently | | Warfarin | Alendronate | Rare; possible alteration of INR reported in post-marketing data | INR elevation | Minor | Monitor INR within 1 to 2 weeks of starting alendronate | | Proton pump inhibitors (PPIs) | Alendronate, risedronate | Raise gastric pH; may modestly improve GI tolerability but do not improve absorption | Slight reduction in GI side effects; no significant pharmacokinetic interaction | Minor | PPI co-prescription acceptable for GI protection; does not negate the 30-min fasting rule | | Denosumab (Prolia) | All BPs | Additive antiresorptive effect | Profound suppression of bone turnover markers; theoretical risk of adynamic bone | Moderate | Not routinely combined; used sequentially; monitor bone turnover markers | | Teriparatide (Forteo) | All BPs | Bisphosphonates blunt the anabolic effect of PTH analogs | Reduced teriparatide efficacy when given simultaneously | Major | Do not co-prescribe; teriparatide should follow, not overlap with, bisphosphonate therapy | | Ranelic acid (strontium ranelate, EU markets) | All oral BPs | Divalent cation chelation (Sr²⁺) | Reduced absorption of both agents | Moderate | Separate by at least 2 hr | | Antineoplastic agents (cisplatin, bevacizumab) | Zoledronic acid | Additive nephrotoxicity; bevacizumab impairs renal perfusion | AKI risk | Moderate | Renal function monitoring before each zoledronic acid infusion |

Calcium and Polyvalent Cation Interactions: The Dominant DDI Category

Chelation with calcium and other polyvalent cations is the single most clinically consequential category of bisphosphonate drug interactions. It applies to every oral formulation in the class.

Mechanism in Detail

Bisphosphonates carry two negatively charged phosphonate groups at physiologic pH. These groups bind with high affinity to divalent and trivalent metal cations, forming insoluble chelate complexes in the stomach and proximal small intestine. Once chelated, the bisphosphonate is too large and polar to cross the intestinal epithelium [4].

A crossover pharmacokinetic study cited in the alendronate prescribing information showed that co-administration with 500 mg calcium carbonate reduced alendronate AUC by approximately 60% [2]. Even 250 mL of mineral water (rich in calcium and magnesium) reduces risedronate absorption by 13 to 27% compared with plain tap water, according to data reviewed in the European Medicines Agency assessment of risedronate [8].

Practical Prescribing Rules

The 30-minute window before food or supplements applies to all weekly and daily oral bisphosphonates. For ibandronate 150 mg monthly tablets, the FDA label specifies 60 minutes before any food or drink other than plain water [9]. Prescribers should counsel patients explicitly: no coffee, juice, dairy, vitamins, antacids, or other medications in that window.

Renal Interactions with IV Bisphosphonates

Intravenous zoledronic acid (5 mg once yearly for osteoporosis; 4 mg every 3 to 4 weeks for oncology indications) and pamidronate carry a distinct interaction profile centered on the kidney.

Nephrotoxicity Mechanisms

Zoledronic acid is eliminated entirely by glomerular filtration and active tubular secretion. At high concentrations in tubular cells, it induces mitochondrial dysfunction and apoptosis. Aminoglycosides, cisplatin, and radiocontrast agents share overlapping tubulotoxic mechanisms [6].

The HORIZON Key Fracture Trial (N=7,765) used 5 mg IV zoledronic acid annually and excluded patients with CrCl <30 mL/min. Acute-phase reactions occurred in 31.6% of patients after the first infusion, predominantly fever, myalgia, and flu-like symptoms, which resolved within 3 days in most cases [10]. Serum creatinine increases of more than 0.5 mg/dL above baseline occurred in 1.2% of zoledronic acid recipients versus 0.4% of placebo recipients (P<0.001) [10].

Hydration as a Drug Interaction Modifier

Loop diuretics and any agent causing volume depletion amplify zoledronic acid nephrotoxicity by reducing renal perfusion during the infusion window. Standard practice is to ensure patients are adequately hydrated before the infusion, defined as at least 500 mL of saline or equivalent in the 2 hours prior, particularly in elderly patients taking furosemide or thiazide diuretics [6].

NSAIDs and GI Toxicity Overlap

Oral bisphosphonates are direct esophageal and gastric irritants. Their mechanism of GI injury involves local contact with mucosa causing cellular toxicity, distinct from the systemic prostaglandin inhibition caused by NSAIDs.

Evidence for Additive Risk

A nested case-control study published in BMJ (N=30,601 bisphosphonate users) found that concurrent NSAID use increased the odds ratio for upper GI complications to 2.5 (95% CI 1.8 to 3.5) compared with bisphosphonate use alone [11]. Aspirin at cardioprotective doses (81 mg) showed a weaker but still elevated OR of 1.4 in the same analysis [11].

Management Options

For patients requiring chronic NSAIDs, switching to an IV bisphosphonate removes the esophageal irritation risk entirely. When oral therapy is preferred, a proton pump inhibitor reduces gastric injury risk, though it does not eliminate the absorption-timing requirement and should not be taken within 30 minutes of the bisphosphonate dose.

Anabolic Agent Interactions: Teriparatide and Abaloparatide

Combining a bisphosphonate with teriparatide (recombinant PTH 1-34) in the same treatment period is a common prescribing error. The DATA trial (N=94) and earlier work by Black et al. Showed that alendronate blunted the increase in bone mineral density (BMD) at the lumbar spine produced by teriparatide, compared with teriparatide alone [12].

The accepted sequencing strategy, endorsed in AACE 2020 guidance [3], is to use teriparatide or abaloparatide as anabolic therapy for 18 to 24 months, then follow immediately with a bisphosphonate to preserve the gained BMD. Beginning teriparatide while a patient is still on an active bisphosphonate reduces its anabolic effect for at least the first 6 to 12 months of therapy.

Glucocorticoid-Induced Osteoporosis: A Special DDI Context

Chronic glucocorticoid use is a pharmacodynamic interaction context rather than a pharmacokinetic one. Glucocorticoids accelerate osteoblast apoptosis, inhibit intestinal calcium absorption, and increase renal calcium wasting, all of which oppose the protective mechanism of bisphosphonates.

The American College of Rheumatology (ACR) 2022 guidelines on glucocorticoid-induced osteoporosis state: "For patients of any age who will be using glucocorticoids at a dose of 2.5 mg/day or more of prednisone equivalent for 3 months or longer, bisphosphonate therapy should be initiated at the same time as the glucocorticoid" [7]. Risedronate and zoledronic acid both carry FDA approval for this indication.

Despite the pharmacodynamic antagonism, the net clinical benefit of bisphosphonate therapy in this population is positive. The ACR recommendation is conditional strong for high-fracture-risk patients. BMD monitoring every 1 to 2 years is appropriate during concurrent glucocorticoid and bisphosphonate therapy to verify that the bisphosphonate is maintaining or improving bone density against the glucocorticoid-driven loss.

Bisphosphonate Drug Holiday and Interaction Considerations at Discontinuation

After 5 years of oral bisphosphonate therapy or 3 years of annual zoledronic acid, guidelines support considering a drug holiday for patients at moderate fracture risk [3]. During the holiday period, residual skeletal drug continues to inhibit bone resorption because of the long bone half-life of nitrogen-containing bisphosphonates.

This residual activity has a clinically relevant interaction implication: starting teriparatide immediately after discontinuing a bisphosphonate still shows some attenuation of anabolic response in the first 6 months. A 12-month washout before starting teriparatide optimizes the anabolic response, though many patients at high fracture risk cannot tolerate that delay.

When transitioning from denosumab to a bisphosphonate, timing is critical. Denosumab cessation without a bridging bisphosphonate causes rapid rebound bone loss, sometimes exceeding the pre-treatment baseline within 12 months. The AACE guidance recommends administering zoledronic acid 5 mg approximately 6 months after the last denosumab dose to blunt the rebound [3].

Monitoring Parameters for Bisphosphonate Prescribers

Adequate monitoring reduces the risk of harm from both the drug itself and its interactions.

Before Starting Therapy

Check serum calcium, 25-hydroxyvitamin D, creatinine, and phosphorus in all patients. Hypocalcemia is a contraindication to starting bisphosphonate therapy; correcting vitamin D deficiency first reduces the risk of post-dose hypocalcemia, particularly after IV zoledronic acid [6]. A 2012 FDA Drug Safety Communication confirmed that severe hypocalcemia, including fatal cases, has occurred in patients receiving IV bisphosphonates who were also vitamin D deficient [13].

During Ongoing Therapy

For IV formulations: check serum creatinine before each infusion. For oral formulations: annual BMD by DXA, periodic serum calcium, and clinical review of interacting medications at every visit. Patients on alendronate or risedronate should be queried at every visit about dysphagia, chest pain, or new-onset heartburn, which may signal esophageal injury.

Dental Evaluation

The American Association of Oral and Maxillofacial Surgeons recommends a dental examination and completion of invasive dental procedures before initiating bisphosphonate therapy for oncology indications, and strongly advises it for long-term osteoporosis therapy [14]. The risk of medication-related osteonecrosis of the jaw (MRONJ) is estimated at 0.001 to 0.01% in osteoporosis patients and rises to 1 to 15% in oncology patients receiving high-dose IV bisphosphonates [14].

Bisphosphonate-Specific Dosing Summary

| Drug | Route | Osteoporosis Dose | CrCl Cutoff | Key Timing Rule | |---|---|---|---|---| | Alendronate (Fosamax) | Oral | 70 mg weekly or 10 mg daily | <35 mL/min: avoid | 30 min before first food/drink/drug | | Risedronate (Actonel) | Oral | 35 mg weekly or 150 mg monthly | <30 mL/min: avoid | 30 min before first food/drink/drug | | Ibandronate (Boniva) | Oral/IV | 150 mg monthly PO; 3 mg IV q3 months | <30 mL/min: avoid IV | 60 min before first food/drink/drug (PO) | | Zoledronic acid (Reclast) | IV | 5 mg once yearly | <35 mL/min: contraindicated | Infuse over ≥15 min; hydrate before infusion | | Pamidronate (Aredia) | IV | 90 mg q3 to 4 weeks (oncology) | Dose-reduce for renal impairment | Infuse over 2 to 4 hr; monitor renal function |